Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 1, 2006, Pages 141-152

  Porta, Camillo ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Immunotherapy; Interferon ; Interleukin 2; Maintenance treatment; Renal cell carcinoma

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 2; ISOTRETINOIN; MEDROXYPROGESTERONE ACETATE; NEXAVAR; PLACEBO; RETINOIC ACID; SORAFENIB; SUNITINIB; THIOCTIC ACID; ALPHA INTERFERON;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RESPONSE; EVIDENCE BASED MEDICINE; HUMAN; HYPOTENSION; IMMUNE RESPONSE; KIDNEY CARCINOMA; LONG TERM CARE; MAINTENANCE THERAPY; METASTASIS; NEPHRECTOMY; REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; DISEASE COURSE; DOSE RESPONSE; IMMUNOLOGY; KIDNEY TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; SURVIVAL;

EID: 33644840168     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.1.141     Document Type: Review

References (89)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int. J. Cancer 55, 891-903 (1993).
3. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 281, 1628-1631 (1999).
4. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol. 166, 1611-1623 (2001).
5. Uzzo RG, Rayman P, Novick AC, Bukovski RM, Finle JH. Molecular mechanisms of immune dysfunction in renal cell carcinoma. In: Bukowski RM, Novick AC (Eds.) Renal Cell Carcinoma: Molecular Biology, Immunology and Clinical Management. Humana Press, NJ, USA, 63-78 (2000).
6. Bohm M, Ittenson A, Philipp C, Rohl FW, Ansorge S, Allhof EP. Complex perioperative immuno-dysfunction in patients with renal cell carcinoma. J. Urol. 166, 831-836 (2001).
7. French LE, Tschopp J. Defective death receptor signaling as a cause of tumor immune escape. Semin. Cancer Biol. 12, 51-55 (2002).
8. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 71, 907-920 (2002).
9. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nature Immunol. 3, 999-1005 (2002).
10. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance and tumor immune escape. J. Cell Physiol. 195, 346-355 (2003).
11. Schwaab T, Schned AR, Heaney JA et al. In vivo description of dendritic cells in human renal cell carcinoma. J. Urol. 162, 291-292 (1999).
12. Kudo D, Rayman P, Horton C et al. Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T-cells. Cancer Res. 63, 1676-1683 (2003).
13. Rayman P, Uzzo RG, Kolenko V et al. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape. Cancer J. Sci. Am. 6(Suppl.1), S81-S87 (2000).
14. Finke JH, Rayman P, George R et al. Tumor-induced sensitivity to apoptosis in T-cells from patients with renal cell carcinoma: role of nuclear factor-κB. Clin. Cancer Res. 7(Suppl.3), S940-S946 (2001).
15. Singh HP, Gupta S, Raina V. Restoration of naive cell repertoire in the appropriate cytokine milieu: a model for preventing cancer relapses. Med. Hypotheses 58, 554-557 (2002).
16. Schirrmacher V. T-cell immunity in the induction and maintenance of a tumor dormant state. Semin. Cancer Biol. 11, 285-295 (2001).
17. Smyth MJ, Cretney E, Kelly JM et al. Activation of NK cell cytotoxicity. Mol. Immunol. 42, 501-510 (2005).
18. Zuckermann FA. Extrathymic CD4/CD8 double-positive T-cells. Vet. Immunol. Immunopathol 72, 55-66 (1999).
19. + phenotype on activated T-cells: possible role of antigen transfer. Hum. Immunol. 55, 1-10 (1997).
20. Diaz-Romero J, Vogt G, Weckbecker G. Coexpression of CD4 and CD8 alpha on rat T-cells in whole blood: a sensitive marker for monitoring T-cell immunosuppressive drugs. J. Immunol. Methods 254, 1-12 (2001).
21. Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150-4166 (1998).
22. Gabrilovich D, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963-2970 (1999).
23. Oyama T, Ran S, Ishida T et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 160, 1224-1232 (1998).
24. Rini B, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 23, 1028-1043 (2005).
25. Goodley PA, Taylor M. Renal cell carcinoma. Curr. Opin. Oncol. 13, 199-203 (2001).
26. Naito S, Koga H, Yokomizo A et al. Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. World J. Surg. 24, 1183-1186 (2000).
27. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163, 408-417 (2000).
28. Amato RJ. Chemotherapy for renal cell carcinoma. Semin. Oncol. 27, 177-186 (2000).
29. Negrier S, Escudier B, Lasser C et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal cell carcinoma. N. Engl. J. Med. 338, 1272-1278 (1998).
30. Dutcher JP. Interleukin-2 based therapy for kidney cancer. Cancer Treat Res. 116, 155-172 (2003).
31. Dutcher JP, Logan T, Gordon M et al. Phase II trial of interleukin-2, interferon α, and 5-fluorouracil in metastatic renal cell cancer: a Cytokine Working Group Study. Clin. Cancer Res. 6, 3442-3450 (2000).
32. Porta C, Danova M, Orengo AM et al. Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro. J. Cell Physiol. 185, 126-134 (2000).
33. Porta C, Rizzo V, Zimatore M, Sartore-Bianchi Z, Danova M, Mutti L. Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity? Lung Cancer 38, 159-162 (2002).
34. Porta C, Moroni M, Bobbio-Pallavicini E, Tinelli C, Regazzi-Bonora M. Nitrate plasma level as a marker of nitric oxide production after subcutaneous interleukin-2 immunotherapy. J. Natl Cancer Inst. 89, 1545 (1997).
35. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 15, 368-381 (1997).
36. McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 (2005).
37. Negrier S, Perol D, Ravaud A et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY-Quattro trial. Proc. Am. Soc. Clin. Oncol. 23, 380s (2005) (Abstract 4511).
38. Baaten G, Voogd AC, Wagstaff J. A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer. Eur. J. Cancer 40, 1127-1144 (2004).
39. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 3, CD001425 (2000).
40. Escudier B, Szczylik C, Eisen T et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 23, 380s (2005) (Abstract 4510).
41. Motzer RJ, Rini BI, Michaelson MD et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 23, 380s (2005) (Abstract 4508).
42. Buzio C, De Palma G, Passalacqua R et al. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br. J. Cancer 76, 541-544 (1997).
43. Vlasveld LT, Hekman A, Vyth-Dreede FA et al. A Phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: immunological aspects. Br. J. Cancer 68, 559-567 (1993).
44. Caligiuri MA. Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin. Oncol. 20, 3-10 (1993).
45. Wiebke EA, Rosenberg SA, Lotze MT. Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J. Clin. Oncol. 6, 1440-1449 (1988).
46. Lenardo MJ. Interleukin-2 programs mouse αβ T-lymphocytes for apoptosis. Nature 353, 858-861 (1999).
47. Raspadori D, Lauria F, Ventura MA et al. Low doses of rIL-2 after autologous bone marrow transplantation induce a 'prolonged' immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas. Ann. Hematol. 71, 175-179 (1995).
48. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nature Med. 3, 505-509 (1997).
49. Buzio C, Andrulli S, Santi R et al. Long-term immunotherapy with low-dose interleukin-2 and Interferon-α in the treatment of patients with advanced renal cell carcinoma. Cancer 92, 2286-2296 (2001).
50. Giacosa R, Santi R, Vaglio A et al. 'Late' regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen. Acta Biomed Ateneo Parmense 75, 126-130 (2004).
51. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84, 964-971 (1994).
52. Jacobson El, Pilaro F, Smith KA. Rational for interleukin-2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl Acad. Sci USA. 93, 10405-10410 (1996).
53. Bernstein ZP, Porter MM, Gould M et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 86, 3287-3294 (1995).
54. Khatri VP, Fehniger TA, Baiocchi RA et al. Ultra low dose interleukin-2 therapy promotes a Type I cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J. Clin. Invest. 101, 1373-1378 (1998).
55. Lissoni P, Barni S, Tancini G et al. Immunoendocrine therapy with interleuchin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapy. Tumori 79, 246-249 (1993).
56. Guida M, Abbate I, Casamassima A et al. Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: biological effects and clinical implications. Cancer Biother. 10, 195-203 (1995).
57. Mantovani G, Macciò G, Madeddu C et al. Immunotherapy (recombinant interleukin-2), hormone therapy (medroxyprogesterone acetate) and anti-oxidant agents as combined maintenance treatment of responders to previous chemotherapy. Int. J. Cancer 18,383-391 (2001).
58. Recchia F, De Filippis S, Rosselli M et al. Phase Ib study of subcutaneous administered interleukin-2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. Clin. Cancer Res. 7, 1251-1257 (2001).
59. Lissoni P, Bordin V, Vaghi M et al. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2. Anticancer Res. 22, 1061-1064 (2002).
60. O'Day SJ, Boasberg PD, Piro L et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin. Cancer Res. 8, 2775-2781 (2002).
61. Mantovani G, Macciò A, Madeddu C et al. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. Oncol Rep. 9, 887-896 (2002).
62. Recchia F, De Filippis S, Rosselli M, Saggio G, Fumagalli L, Rea S. Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a Phase II study. Int. J. Oncol. 20, 1275-1282 (2002).
63. Tourani JM, Pfister C, Tubiana N et al. Subcutaneous interleukin-2 and interferon α administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, Phase II, nonrandomized study with sequential analysis design - The Subcutaneous Administration Propeukin Program Co-operative Group. J. Clin. Oncol. 21, 3987-3994 (2003).
64. Recchia F, Saggio G, Cesta A et al. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy. AntiCancer Res. 25, 3149-3157 (2005).
65. Recchia F, Saggio G, Cesta A et al. Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer. Int. J. Oncol. 27, 1039-1046 (2005).
66. Pavone L, Andrulli S, Santi R, Majori M, Buzio C. Long-term treatment with low doses of interleukin-2 and interferon-α: immunological effects in advanced renal cell cancer. Cancer Immunol. Immunother. 50, 82-86 (2001).
67. Meropol NJ, Porter M, Blumenson LE et al. Daily subcutaneous injection of low-dose interleukin-2 expands natural killer cells in vivo without significant toxicity. Clin. Cancer Res. 2,669-677 (1996).
68. + cells: examination of morphology, function, T-cell receptor rearrangement, and pore-forming protein expression. Cell Immunol. 136, 495-496 (1991).
69. dim natural killer cell subset in patients with cancer. Eur. J. Immunol. 33, 119-124 (2003).
70. Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J. Immunother. 26, 394-402 (2003).
71. Moroni M, Porta C, De Amici M, Quaglini S, Cattabiani MA, Buzio C. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low doses subcutaneous interleukin-2 and interferon in renal cell carcinoma patients. Haematologica 85, 298-303 (2000).
72. Hartung HP, Zanker B, Bitter-Suermann D. Influence of macrophage activation on the synthesis of complement components C2, C3, C4. Ad. Exp. Med. Biol. 155, 525-529 (1982).
73. Vile RG, Chong H, Dorudi S. The immunosurveillance of cancer: specific and non-specific mechanisms. Tumor Immunology, Immunotherapy and Cancer vaccines. Dalgleish AG, Browning M (Eds.). Cambridge University Press, Cambridge, UK, 7-38 (1996).
74. Lissoni P, Tisi E, Brivio F et al. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur. J. Cancer 27, 1014-1016 (1991).
75. Flamm J. Tumor-associated tissue inflammatory reaction and eosinophilia in primary superficial bladder cancer. Urology 40, 180-185 (1992).
76. Thompson AC, Bradley PJ, Griffin NR. Tumor-associated tissue eosinophdia and long-term prognosis for carcinoma of the larynx. Am. J. Surg. 168, 469-471 (1994).
77. Samoszuk M. Eosinophils and human cancer. Histol. Histopathol. 12, 807-812 (1997).
78. Huland E, Huland H. Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res. Clin. Oncol. 118, 463-467 (1992).
79. Rivoltini L, Viggiano V, Spinazzè S et al. In vitro antitumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin-2. Role of interleukin-5. Int. J. Cancer 54, 8-15 (1993).
80. Trulson A, Nilsson S, Venge P. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br. J. Haematol. 98, 312-314 (1997).
81. Moroni M, Porta C, Gritti D et al. Cationic protein-rich supernatants of cultured eosinophils from IL-2-treated patients have no cytotoxic activity on human renal cell carcinoma and melanoma cells: a preliminary report. Ann. NY Acad. Sci. 832, 295-303 (1997).
82. Porta C, Moroni M, De Amici M. Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy. Br. J. Haematol. 100, 607-609 (1998).
83. Clark JI, Gaynor ER, Martone B et al. Daily subcutaneous ultra-low-dose interleukin-2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma. Clin. Cancer Res. 5, 2374-2380 (1999).
84. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louise AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
85. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell carcinoma. Cancer J. Sci. Am. 3(Suppl. 1), S79-S84 (1997).
86. Negrier S, Escudier B, Lasser C et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both, in metastatic renal cell carcinoma. N. Engl. J. Med. 338, 1272-1278 (1998).
87. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271, 907-913 (1994).
88. Porta C, Passalacqua R, Caminiti C et al. Chronic low-dose sc. interleukin-2 (IL-2) and α-Interferon (α-IFN) in advanced renal cell carcinoma (ARCC): preliminary efficacy results of an Italian Oncology Group for Clinical Research (GOIRC) trial. 2nd International Kidney Cancer Symposium, IL, USA, October (2001).
89. Passalacqua R, Buzio C, Dalla Chiesa M et al. Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-α (IFN) for metastatic renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol. 23, 404s (2005) (Abstract 4605).